PharmaCyte Biotech Inc (PMCB)

Healthcare | Biotechnology
Income Statement (Quarterly) 2025-07-31 2025-01-31 2024-10-31 2024-07-31
Revenue 0 0 0 0
Cost of Revenue 0 0 0 0
Gross Profit 0 0 0 0
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 753,148 609,193 117,572 783,387
Operating Expenses 848,305 960,252 1,106,060 1,268,887
Operating Income -848,305 -960,252 -1,106,060 -1,268,887
Interest Expense 0 0 0 0
Income Before Tax -8,360,096 -3,045,328 -1,469,560 23,421,355
Income Tax Expense 0 0 0 0
Net Income -8,360,096 -3,045,328 -1,469,560 23,421,355
Per Share
EPS -1.23 -0.44 -0.39 1.90
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Revenue 0 0 0 0 0
Cost of Revenue 0 0 0 0 0
Gross Profit 0 0 0 0 0
Operating Expenses
R&D Expenses 0 0 0 0 0
SG&A Expenses 3,939,446 2,117,000 4,752,000 3,701,077 2,706,732
Operating Expenses 4,377,862 6,520,000 6,455,000 4,392,014 3,622,981
Operating Income -4,377,862 -8,520,000 -6,455,000 -4,392,014 -3,622,981
Interest Expense 0 0 0 509 3,046
Income Before Tax 30,656,050 333,763 -4,316,000 -4,239,161 -3,551,236
Income Tax Expense 0 0 -1,937,000 -153,362 0
Net Income 30,656,050 333,763 -4,316,000 -4,085,799 -3,551,236
Per Share
EPS 3.19 -1.80 -0.22 -0.26 -2.45
EPS Diluted 0.00 0.00 0.00 0.00 0.00
Balance Sheet (Quarterly) 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Assets
Cash and Cash Equivalents 15,172,163 50,179,968 68,039,936 85,400,656
Short Term Investments 366,316 0 0 0
Net Receivables 3,696,000 0 0 0
Inventory 0 0 0 0
Total Current Assets 22,375,238 50,439,768 68,147,617 85,494,828
Property Plant Equipment 0 0 0 0
Goodwill and Intangibles 1,549,427 1,549,427 3,549,427 3,549,427
Total Assets 55,168,353 59,903,883 73,276,925 90,624,136
Liabilities
Account Payables 399,204 389,369 128,281 205,361
Short Term Debt 0 0 0 0
Total Current Liabilities 2,914,284 7,421,264 586,581 704,370
Long Term Debt 0 0 0 0
Total Liabilities 3,277,284 20,389,264 586,581 704,370
Shareholders Equity
Retained Earnings -84,968,960 -115,625,010 -115,958,773 -111,648,656
Total Shareholders Equity 51,891,069 39,514,619 72,690,344 89,919,766
Balance Sheet (Annual) 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Assets
Cash and Cash Equivalents 15,172,163 50,179,968 68,039,936 85,400,656 2,202,106
Short Term Investments 366,316 0 0 0 0
Net Receivables 3,696,000 0 0 0 0
Inventory 0 0 0 0 0
Total Current Assets 22,375,238 50,439,768 68,147,617 85,494,828 2,275,237
Property Plant Equipment 0 0 0 0 0
Goodwill and Intangibles 1,549,427 1,549,427 3,549,427 3,549,427 3,549,427
Total Assets 55,168,353 59,903,883 73,276,925 90,624,136 7,404,229
Liabilities
Account Payables 399,204 389,369 128,281 205,361 172,261
Short Term Debt 0 0 0 0 0
Total Current Liabilities 2,914,284 7,421,264 586,581 704,370 724,778
Long Term Debt 0 0 0 0 0
Total Liabilities 3,277,284 20,389,264 586,581 704,370 724,778
Shareholders Equity
Retained Earnings -84,968,960 -115,625,010 -115,958,773 -111,648,656 -107,409,495
Total Shareholders Equity 51,891,069 39,514,619 72,690,344 89,919,766 6,679,451
Cash Flow Statement (Quarterly) 2025-04-30 2024-04-30 2023-04-30 2022-04-30
Operating Activities
Net Income 30,656,050 333,763 -4,315,993 -4,239,161
Depreciation & Amortization 0 0 0 0
Stock Based Compensation 478,637 675 645,406 77,956
Change in Working Capital 1,356,333 298,894 -297,166 9,040
Operating Cash Flow -2,978,296 -2,151,457 -3,793,731 -4,117,319
Investing Activities
Capital Expenditure -4 0 0 0
Investments 0 0 0 0
Investing Cash Flow -7,000,000 -5,000,000 0 0
Financing Activities
Debt Repayment 0 0 0 -50,805
Common Stock Issued/Repurchased -25,029,151 -10,708,003 -13,559,743 87,362,049
Dividends Paid -1,129,759 0 0 0
Financing Cash Flow -25,029,151 -10,708,003 -13,559,743 87,311,244
Summary
Free Cash Flow -2,978,296 -2,151,457 -3,793,731 -4,117,319
Net Change in Cash -35,007,805 -17,859,968 -17,360,720 83,198,550
Cash Flow Statement (Annual) 2025-04-30 2024-04-30 2023-04-30 2022-04-30 2021-04-30
Operating Activities
Net Income 30,656,050 333,763 -4,315,993 -4,239,161 -3,551,236
Depreciation & Amortization 0 0 0 0 0
Stock Based Compensation 478,637 675 645,406 77,956 370,829
Change in Working Capital 1,356,333 298,894 -297,166 9,040 -145,608
Operating Cash Flow -2,978,296 -2,151,457 -3,793,731 -4,117,319 -3,330,889
Investing Activities
Capital Expenditure -4 0 0 0 0
Investments 0 0 0 0 0
Investing Cash Flow -7,000,000 -5,000,000 0 0 0
Financing Activities
Debt Repayment 0 0 0 -50,805 -62,440
Common Stock Issued/Repurchased -25,029,151 -10,708,003 -13,559,743 87,362,049 4,699,247
Dividends Paid -1,129,759 0 0 0 0
Financing Cash Flow -25,029,151 -10,708,003 -13,559,743 87,311,244 4,636,807
Summary
Free Cash Flow -2,978,296 -2,151,457 -3,793,731 -4,117,319 -3,330,889
Net Change in Cash -35,007,805 -17,859,968 -17,360,720 83,198,550 1,307,245